# Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

> **NCT00905593** · — · APPROVED_FOR_MARKETING · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT00905593
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** 2008-09
- **Primary completion:** 2011-04
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2012-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00905593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00905593, "Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00905593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*